One case report of T-DM1 in treatment of recurrent metastatic breast cancer / 中华内分泌外科杂志

ABSTRACT

HER2-positive breast cancer is highly aggressive and prone to recurrence and metastasis. T-DM1 (Ado-Trastuzumab Emtansine) is a new anti-HER2 targeted drug with targeting therapeutic effect and cytotoxic killing. It was officially approved by the National Medical Products Administration in February 2020, but there are few reports about its application in China. In this paper, a case of locally advanced HER2-positive breast cancer treated with T-DM1 was reported, and relevant literature was reviewed to improve the understanding of targeted drug T-DM1, in order to provide a new anti-HER2 treatment option for HER2-positive breast cancer patients.